Andrei S. Shkoda

Andrei S. Shkoda

Auto-generated profile, based on publicly available information

Andrei S. Shkoda

L.A. Vorokhobov City Clinical Hospital No. 67 of the Moscow Healthcare Department

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2020 in Obstetrics, Gynecology and Reproduction
Verified
Journal Article
Open access
PDF file
AMAlexander Makatsariya
Alexander Makatsariya
KGK. N. Grigoreva
K. N. Grigoreva
MMMarat Mingalimov
Marat Mingalimov
VBVictoria Bitsadze
Victoria Bitsadze
JKJamilya Khizroeva
Jamilya Khizroeva
DMD. V. Mitryuk
D. V. Mitryuk
COVID-19 is an infectious disease caused by the beta-coronavirus SARS-CoV-2 that in 2020 has spread worldwide. In most severe patients, the clinical picture begins with respiratory failure further deteriorating up to multiple organ failure. Development of coagulopathy is the most adverse prognostic. Analyzing currently available clinical data revealed that 71.4 % and 0.6 % of survivors and fatal cases, respectively, demonstrated signs of overt disseminated intravascular coagulation (DIC). Monitoring D-dimer level, prothrombin time, platelet count and fibrinogen content is important for determining indications for treatment and hospitalization in COVID-19 patients. In case such parameters deteriorate, a more pro-active “aggressive” intensive care should be applied. Low molecular weight heparin (LMWH) should be administered to all patients with diagnosed COVID-19 infection (including non-critical patients) requiring hospitalization, but having no contraindications to LMWH.

4 November 2021 in Obstetrics, Gynecology and Reproduction
Verified
Journal Article
Open access
PDF file
AMAlexander Makatsariya
Alexander Makatsariya
ESEkaterina V. Slukhanchuk
Ekaterina V. Slukhanchuk
VBVictoria Bitsadze
Victoria Bitsadze
JKJamilya Khizroeva
Jamilya Khizroeva
MTMaria V. Tretyakova
Maria V. Tretyakova
EGE. Grandone
E. Grandone
The rate of thrombosis and disseminated intravascular coagulation (DIC) has been increasing in COVID-19 patients. Key features related to such condition include minimal or no risk of bleeding, moderate thrombocytopenia, high plasma fibrinogen as well as complement components level in the areas of thrombotic microangiopathy. The clinical picture is not typical for classic DIC. This review systematizes the pathogenetic mechanisms of hypercoagulation in sepsis and its extreme forms in patients with COVID-19. The latter consist of the thrombosis-related immune mechanisms, the complement activation, the macrophage activation syndrome, the formation of antiphospholipid antibodies, the hyperferritinemia, and the dysregulation of the renin-angiotensin system. Taking into consideration the pathogenetic mechanisms, the biomarkers had been identified related to the prognosis of the disease development. Patients with pre-existing cardiovascular disease and other risk factors, including obesity, diabetes, hypertension, and aging pose the peak risk of dying from COVID-19. We also summarize new data on platelet and endothelial dysfunction, immunothrombosis, and, as a result, thrombotic storm as essential components of COVID-19 severe features.

26 July 2020 in Obstetrics, Gynecology and Reproduction
Verified
Journal Article
Open access
PDF file
JKJamilya Khizroeva
Jamilya Khizroeva
AMAlexander Makatsariya
Alexander Makatsariya
VBVictoria Bitsadze
Victoria Bitsadze
MTM. V. Tretyakova
M. V. Tretyakova
ESEkaterina V. Slukhanchuk
Ekaterina V. Slukhanchuk
DBDmitry V. Blinov
Dmitry V. Blinov
The pandemic of a novel coronavirus infection COVID-19 has become a real challenge to the mankind and medical community and has raised a number of medical and social issues. Based on the currently available information on COVID-19 clinical cases, it follows that COVID-19 patients in critical condition exhibit a clinical picture of disseminated intravascular coagulation (DIC), septic shock with developing multiple organ failure, which justifies use of anticoagulant therapy in COVID-19 patients. In addition to isolating virus RNA from biological material and polymerase chain reaction diagnostics, use of simple and easily accessible laboratory blood markers is necessary for management of COVID-19 patients. If the activation of coagulation processes is sufficient enough, consumption of platelets and blood clotting factors can be diagnosed by laboratory methods as prolongation of routine blood clotting tests and increasing thrombocytopenia. Hyperfibrinogenemia, increased D-dimer level, prolonged prothrombin time, thrombocytopenia, lymphopenia, leukocytopenia, increased concentration of interleukin-6 and ferritin are observed in most COVID19 patients. The degree of increase in these changes correlates with severity of the inflammatory process and serves as a prognostically unfavorable sign. Here we discuss value of laboratory monitoring playing an essential role in such pathological crisis that contributes to patient screening, diagnosis as well as further monitoring, treatment and rehabilitation.

12 April 2021 in Annals of the Russian academy of medical sciences
Verified
Journal Article
Open access
PDF file
VBVictoria Bitsadze
Victoria Bitsadze
ESEkaterina V. Slukhanchuk
Ekaterina V. Slukhanchuk
JKJamilya Khizroeva
Jamilya Khizroeva
MTMaria V. Tretyakova
Maria V. Tretyakova
ASAndrei S. Shkoda
Andrei S. Shkoda
ГЖГрис Жан-Кристоф
Грис Жан-Кристоф
This article summarizes numerous studies on the relationship of biological processes such as inflammation and thrombosis. The huge role of neutrophils and the extracellular neutrophil traps (NETs) secreted by them has been demonstrated. The discovery of NETs has opened new horizons in the understanding of neutrophil biology and the role of these cells in the body. The use of chromatin in combination with the intracellular proteins, as an effective antimicrobial agent has ancient roots and changes our understanding of chromatin only as a carrier of genetic information. Through NETs, neutrophils can contribute to the development of pathological venous and arterial thrombosis or immunothrombosis, as well as atherosclerosis. NETs release has been shown to be one of the causes of thrombosis in conditions such as sepsis and cancer. The presence of NETs in these diseases and conditions makes it possible to use them or individual components as potential biomarkers. NETs and their components may be attractive as therapeutic targets. Further studies of neutrophils and NETs are needed to develop new approaches to the diagnosis and treatment of inflammatory and thrombotic conditions. Perhaps long-forgotten drugs will find a new area for effective use.

27 May 2021 in The Journal of Maternal-Fetal & Neonatal Medicine
Verified
Journal Article
Closed access
JKJamilya Khizroeva
Jamilya Khizroeva
VBVictoria Bitsadze
Victoria Bitsadze
ATAngela Tincani
Angela Tincani
AMAlexander Makatsariya
Alexander Makatsariya
MAMadina Arslanbekova
Madina Arslanbekova
TMTamara Mashkova
Tamara Mashkova
The current recommended therapy of obstetric antiphospholipid syndrome (APS) is a long-term anticoagulant therapy that affects the final event, namely, when the thrombosis has already occurred. Unf...

9 September 2021 in Obstetrics, Gynecology and Reproduction
Verified
Journal Article
Open access
PDF file
AMAlexander Makatsariya
Alexander Makatsariya
ESEkaterina V. Slukhanchuk
Ekaterina V. Slukhanchuk
VBVictoria Bitsadze
Victoria Bitsadze
JKJamilya Khizroeva
Jamilya Khizroeva
MTMaria V. Tretyakova
Maria V. Tretyakova
Ismail ElalamyIsmail Elalamy
Ismail Elalamy
Numerous studies have proven a close relationship between inflammatory diseases and the state of hypercoagulability. In fact, thromboembolic complications represent one of the main causes of disability and mortality in acute and chronic inflammatory diseases, cancer and obstetric complications. Despite this, the processes of hemostasis and immune responses have long been considered separately; currently, work is underway to identify the molecular basis for a relationship between such systems. It has been identified that various pro-inflammatory stimuli are capable of triggering a coagulation cascade, which in turn modulates inflammatory responses. Neutrophil extracellular traps (NETs) are the networks of histones of extracellular DNA generated by neutrophils in response to inflammatory stimuli. The hemostasis is activated against infection in order to minimize the spread of infection and, if possible, inactivate the infectious agent. Another molecular network is based on fibrin. Over the last 10 years, there has been accumulated a whole body of evidence that NETs and fibrin are able to form a united network within a thrombus, stabilizing each other. Similarities and molecular cross-reactions are also present in the processes of fibrinolysis and lysis of NETs. Both NETs and von Willebrand factor (vWF) are involved in thrombosis as well as inflammation. During the development of these conditions, a series of events occurs in the microvascular network, including endothelial activation, NETs formation, vWF secretion, adhesion, aggregation, and activation of blood cells. The activity of vWF multimers is regulated by the specific metalloproteinase ADAMTS-13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13). Studies have shown that interactions between NETs and vWF can lead to arterial and venous thrombosis and inflammation. In addition, the contents released from activated neutrophils or NETs result in decreased ADAMTS-13 activity, which can occur in both thrombotic microangiopathies and acute ischemic stroke. Recently, NETs have been envisioned as a cause of endothelial damage and immunothrombosis in COVID-19. In addition, vWF and ADAMTS-13 levels predict COVID-19 mortality. In this review, we summarize the biological characteristics and interactions of NETs, vWF, and ADAMTS-13, the effect of NETs on hemostasis regulation and discuss their role in thrombotic conditions, sepsis, COVID-19, and obstetric complications.